Linked Life Data

19948450

Source:http://linkedlifedata.com/resource/pubmed/id/19948450

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2009-12-23
pubmed:abstractText
The treatment of the advanced ovarian adenocarcinoma, most frequently stage at diagnostic, relies on association of surgery and chemotherapy. The current standard is the association carboplatine-paclitaxel. In spite of this treatment, relapses are frequent, and the prognosis thus remains very reserved. Presently the current areas of research aim at both improving the efficiency of treatments and decreasing their toxicity. So the various trials dealt with the use of the other cytotoxics having proved efficiency against relapses either in double-agent therapy or in association in the current standard, or in the administration of the chemotherapy by intra peritoneal way. They also investigated the possibility of pursuing the therapeutic sequence by a treatment of maintenance or consolidation. As for numerous cancerous pathologies, the targeted therapies, notably the antiangiogenic one, represent an important hope in the treatment of the ovarian cancer.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1769-6917
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
96
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1207-13
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[First line chemotherapy of advanced epithelial ovarian cancer].
pubmed:affiliation
Institut Gustave-Roussy, Comité de Gynécologie, 39 Rue Camille-Desmoulins, 94805 Villejuif, France. lhomme@igr.fr
pubmed:publicationType
Journal Article, English Abstract